Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Novartis

Novartis
1996 FOUNDED
PUBLIC STATUS
>100K EMPLOYEES
NOVN STOCK SYMBOL
97 INVESTMENTS
$96.13 SHARE PRICE (As of Friday Closing)
Description

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total sales.

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
SWX
Primary Office
  • PO Box 4002
  • 4002 Basel
  • Switzerland

+41 061 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Novartis’s full profile, request a free trial.

Novartis Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$74.03 - $96.27 $218B $95.07 $5.14 5.24M 2.26B

Novartis Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 220,087,044 206,880,815 210,987,007 183,542,900
Revenue 54,925,000 53,166,000 50,135,000 49,436,000
EBITDA 16,086,000 21,390,000 15,742,000 14,524,000
Net Income 11,802,000 12,611,000 7,703,000 6,712,000
Total Assets 115,971,000 145,563,000 133,079,000 130,124,000
Total Debt 30,116,000 32,090,000 28,425,000 23,686,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Novartis Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Novartis‘s full profile, request access.

Request full access to PitchBook

Novartis Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Kenilworth, NJ 00000
00000000000 Formerly PE-Backed Cambridge, United Kingdom 00000 000 00000000 000
000000 00000000 Corporation Tokyo, Japan 00000 00.000 00000000 00.000
000000-0000000 000 Corporation Karachi, Pakistan 0000
00000 Corporate Backed or Acquired Mumbai, India 00000 00000000
To view this company’s complete list of competitors, request access »

Novartis Investments & Acquisitions (97)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 09-Jan-2020 00000 00000 00 0000 Biotechnology
000 000000000 0000 06-Jan-2020 000000000000000000 00.00 Biotechnology
00000 0000000000 ( 11-Nov-2019 000000000000000000 00000 Pharmaceuticals 0000000 0000000
000000 00000000000 23-Oct-2019 000000000 0000 Drug Discovery
SiO2 Medical Products 02-Oct-2019 PE Growth/Expansion 0000 Plastic Containers and Packaging
To view this company’s complete investment and acquisition history, request access »

Novartis Exits (22)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000000 01-Aug-2017 00000 00000 00 000.00 Completed
  • 14 buyers
00000 00000000000 29-Aug-2016 00000 00000 00 0000 Completed
  • 9 buyers
000 000000000000 22-Jun-2016 00000 00000 00 0000 Completed
  • 3 buyers
00000 00000000000 14-Aug-2015 00000 00000 00 000.00 Completed
  • 3 buyers
GSK Consumer Healthcare 02-Mar-2015 Joint Venture 0000 Completed
  • 2 buyers
To view this company’s complete exits history, request access »

Novartis Subsidiaries (13)

Company Name Industry Location Founded
Cellforcure Pharmaceuticals Les Ulis, France 2013
000000 Drug Discovery Bannockburn, IL 0000
00000 0000000000 0 Corporate Pension New York, NY 0000
00000000 000000000 Acquirer Cambridge, MA 0000
00000000 000000000 Pharmaceuticals Saint-Genis-Pouilly, France 0000
To view this company’s complete subsidiary history, request access »

Novartis Executive Team (73)

Name Title Board
Seat
Contact
Info
Paul Hudson Chief Executive Officer
Richard Francis Chief Executive Officer
Susanne Schaffert Chief Executive Officer
Vasant Narasimhan MD Chief Executive Officer
Harry Kirsch Chief Financial Officer

27 Former Executives

You’re viewing 5 of 73 executives. Get the full list »

Novartis Board Members (7)

Name Representing Role Since Contact
Info
000 00000 Self Board Member 000 0000
0000000 0000 Novartis Board Member 000 0000
000000 00000 00.0 Novartis Board Member & Vice Chairman 000 0000
00000 000000000 00.0 Novartis Chairman & Board Member 000 0000
0000000 0000000 Self Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »